Author

Teri Watkins

Stanford University - Cited by 43,402 - pharmacogenomics - pharmacogenetics

Biography

Teri Watkins,  Mississippi State University, Mississippi State, MS, USA. He  has published more than 30 articles, In the field of Environment, Geospatial Science, Natural Disasters,Earth Sciences, Geographic Information System. 
Title
Cited by
Year
ACMG SF v3. 0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)
DT Miller, K Lee, WK Chung, AS Gordon, GE Herman, TE Klein, ...Genetics in medicine 23 (8), 1381-1390, 2021202
337
2021
An evidence‐based framework for evaluating pharmacogenomics knowledge for personalized medicine
M Whirl‐Carrillo, R Huddart, L Gong, K Sangkuhl, CF Thorn, R Whaley, ...Clinical Pharmacology & Therapeutics 110 (3), 563-572, 2021202
228
2021
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs
KN Theken, CR Lee, L Gong, KE Caudle, CM Formea, A Gaedigk, ...Clinical Pharmacology & Therapeutics 108 (2), 191-200, 2020202
204
2020
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy
KR Crews, AA Monte, R Huddart, KE Caudle, ED Kharasch, A Gaedigk, ...Clinical Pharmacology & Therapeutics 110 (4), 888-896, 2021202
196
2021
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing
JJ Lima, CD Thomas, J Barbarino, Z Desta, SL Van Driest, N El Rouby, ...Clinical Pharmacology & Therapeutics 109 (6), 1417-1423, 2021202
160
2021
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and …
DT Miller, K Lee, AS Gordon, LM Amendola, K Adelman, SJ Bale, ...Genetics in Medicine 23 (8), 1391-1398, 2021202
120
2021
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update
JH Karnes, AE Rettie, AA Somogyi, R Huddart, AE Fohner, CM Formea, ...Clinical Pharmacology & Therapeutics 109 (2), 302-309, 2021202
103
2021
Review and consensus on pharmacogenomic testing in psychiatry
CA Bousman, SA Bengesser, KJ Aitchison, AT Amare, H Aschauer, ...Pharmacopsychiatry 54 (01), 5-17, 2021202
100
2021
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
CR Lee, JA Luzum, K Sangkuhl, RS Gammal, MS Sabatine, CM Stein, ...Clinical Pharmacology & Therapeutics 112 (5), 959-967, 2022202
98
2022
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal …
RM Cooper‐DeHoff, M Niemi, LB Ramsey, JA Luzum, EK Tarkiainen, ...Clinical Pharmacology & Therapeutics 111 (5), 1007-1021, 2022202
77
2022
Pharmacogenetics at scale: an analysis of the UK Biobank
G McInnes, A Lavertu, K Sangkuhl, TE Klein, M Whirl‐Carrillo, RB AltmanClinical Pharmacology & Therapeutics 109 (6), 1528-1537, 2021202
77
2021
PharmVar GeneFocus: CYP2C19
MR Botton, M Whirl‐Carrillo, AL Del Tredici, K Sangkuhl, LH Cavallari, ...Clinical Pharmacology & Therapeutics 109 (2), 352-366, 2021202
68
2021
ACMG SF v3. 1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG)
DT Miller, K Lee, NS Abul-Husn, LM Amendola, K Brothers, WK Chung, ...Genetics in Medicine 24 (7), 1407-1414, 2022202
60
2022
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
JP Lewis, JD Backman, JL Reny, TO Bergmeijer, BD Mitchell, MD Ritchie, ...European Heart Journal-Cardiovascular Pharmacotherapy 6 (4), 203-210, 2020202
57
2020
Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT‐RNR1 Genotype
JH McDermott, J Wolf, K Hoshitsuki, R Huddart, KE Caudle, ...Clinical Pharmacology & Therapeutics 111 (2), 366-372, 2022202
43
2022
PharmVar and the landscape of pharmacogenetic resources
A Gaedigk, M Whirl-Carrillo, VM Pratt, NA Miller, TE KleinClinical pharmacology and therapeutics 107 (1), 43, 2020202
39
2020
Expanding evidence leads to new pharmacogenomics payer coverage
PE Empey, VM Pratt, JM Hoffman, KE Caudle, TE KleinGenetics in Medicine 23 (5), 830-832, 2021202
39
2021
Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation.
A Gaedigk, ST Casey, M Whirl-Carrillo, NA Miller, TE KleinClinical pharmacology and therapeutics 110 (3), 542-545, 2021202
36
2021
PharmVar GeneFocus: CYP2C9
K Sangkuhl, K Claudio‐Campos, LH Cavallari, JAG Agundez, ...Clinical Pharmacology & Therapeutics 110 (3), 662-676, 2021202
31
2021
PharmVar GeneFocus: CYP2B6
Z Desta, A El‐Boraie, L Gong, AA Somogyi, VM Lauschke, C Dandara, ...Clinical Pharmacology & Therapeutics 110 (1), 82-97, 2021202
30
2021

Referred From: https://scholar.google.com/citations?hl=en&user=3yCig6AAAAAJ

Cited by
Citations 43402
h-index 103
i10-index 278
Recommended Journals
Open Access Journals